Skip to main content
Erschienen in: Uro-News 10/2022

03.10.2022 | Ejakulationsstörungen | Fortbildung

Minimalinvasive Techniken bei BPH

Behandlunsmöglichkeiten bei der benignen Prostatahyperplasie

verfasst von: Dr. med. Benedikt Becker, Dr. med. Sophia Hook

Erschienen in: Uro-News | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Auszug

Die transurethrale Resektion der Prostata verliert zunehmend an Boden gegenüber neuen, minimalinvasiven Techniken. Auf der anderen Seite gibt es auch hier nach wie vor Einschränkungen und Rückschläge. Die Therapieentscheidung hängt darum mehr denn je von den Therapiezielen beim jeweiligen Patienten ab. …
Literatur
1.
Zurück zum Zitat Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol 2017;4:148-51 Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol 2017;4:148-51
2.
Zurück zum Zitat Sun Y et al. Study of phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Minerva Urol Nefrol 2020;72:13-21 Sun Y et al. Study of phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Minerva Urol Nefrol 2020;72:13-21
3.
Zurück zum Zitat Zhang Y et al. Efficacy and safety of enucleation vs. resection of prostate for treatment of benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. Prostate Cancer Prostatic Dis 2019;22:493-508 Zhang Y et al. Efficacy and safety of enucleation vs. resection of prostate for treatment of benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. Prostate Cancer Prostatic Dis 2019;22:493-508
4.
Zurück zum Zitat Kampantais S et al. Assessing the Learning Curve of Holmium Laser Enucleation of Prostate (HoLEP). A Systematic Review. Urology 2018;120:9-22 Kampantais S et al. Assessing the Learning Curve of Holmium Laser Enucleation of Prostate (HoLEP). A Systematic Review. Urology 2018;120:9-22
5.
Zurück zum Zitat Lai S et al. Comparison of photoselective green light laser vaporisation versus traditional transurethral resection for benign prostate hyperplasia: an updated systematic review and meta-analysis of randomised controlled trials and prospective studies. BMJ Open 2019;9:e028855 Lai S et al. Comparison of photoselective green light laser vaporisation versus traditional transurethral resection for benign prostate hyperplasia: an updated systematic review and meta-analysis of randomised controlled trials and prospective studies. BMJ Open 2019;9:e028855
7.
Zurück zum Zitat Desai M et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trial. BJU Int 2019;124:321-8 Desai M et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trial. BJU Int 2019;124:321-8
8.
Zurück zum Zitat Gilling P et al. Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained. Adv Ther 2019;36:1326-36 Gilling P et al. Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained. Adv Ther 2019;36:1326-36
9.
Zurück zum Zitat Gilling PJ et al. Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH. Can J Urol 2022;29:10960-8 Gilling PJ et al. Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH. Can J Urol 2022;29:10960-8
10.
Zurück zum Zitat Abt D et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ 2018;361:k2338 Abt D et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ 2018;361:k2338
11.
Zurück zum Zitat Zumstein V et al. Prostatic Artery Embolization versus Standard Surgical Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Metaanalysis. Eur Urol Focus 2019;5:1091-100 Zumstein V et al. Prostatic Artery Embolization versus Standard Surgical Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Metaanalysis. Eur Urol Focus 2019;5:1091-100
12.
Zurück zum Zitat Abt D et al. Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: 2-yr Outcomes of a Randomised, Open-label, Single-centre Trial. Eur Urol 2021;80:34-42 Abt D et al. Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: 2-yr Outcomes of a Randomised, Open-label, Single-centre Trial. Eur Urol 2021;80:34-42
13.
Zurück zum Zitat McVary KT et al. Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. Urology 2019;126:171-9 McVary KT et al. Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. Urology 2019;126:171-9
14.
Zurück zum Zitat Roehrborn CG et al. Convective Thermal Therapy: Durable 2-Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. J Urol 2017;197:1507-16 Roehrborn CG et al. Convective Thermal Therapy: Durable 2-Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. J Urol 2017;197:1507-16
15.
Zurück zum Zitat Elterman D et al. Prostatic urethral lift (UroLift) versus convective water vapor ablation (Rezum) for minimally invasive treatment of BPH: a comparison of improvements and durability in 3-year clinical outcomes. Can J Urol 2021;28:10824-33 Elterman D et al. Prostatic urethral lift (UroLift) versus convective water vapor ablation (Rezum) for minimally invasive treatment of BPH: a comparison of improvements and durability in 3-year clinical outcomes. Can J Urol 2021;28:10824-33
16.
Zurück zum Zitat Sievert K-D et al. Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years. World J Urol 2019;37:1353-60 Sievert K-D et al. Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years. World J Urol 2019;37:1353-60
17.
Zurück zum Zitat Roehrborn CG et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 2017;24:8802-13 Roehrborn CG et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 2017;24:8802-13
18.
Zurück zum Zitat Gratzke C et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int 2017;119:767-75 Gratzke C et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int 2017;119:767-75
19.
Zurück zum Zitat Porpiglia F et al. 3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. BJU Int 2018;122:106-12 Porpiglia F et al. 3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. BJU Int 2018;122:106-12
20.
Zurück zum Zitat Kadner G et al. Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study. World J Urol 2020;38:3235-44 Kadner G et al. Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study. World J Urol 2020;38:3235-44
21.
Zurück zum Zitat Amparore D et al. First- and Second-Generation Temporary Implantable Nitinol Devices As Minimally Invasive Treatments for BPH-Related LUTS: Systematic Review of the Literature. Curr Urol Rep 2019;20:47 Amparore D et al. First- and Second-Generation Temporary Implantable Nitinol Devices As Minimally Invasive Treatments for BPH-Related LUTS: Systematic Review of the Literature. Curr Urol Rep 2019;20:47
22.
Zurück zum Zitat Chughtai B et al. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial.Urology 2021;153:270-6 Chughtai B et al. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial.Urology 2021;153:270-6
Metadaten
Titel
Minimalinvasive Techniken bei BPH
Behandlunsmöglichkeiten bei der benignen Prostatahyperplasie
verfasst von
Dr. med. Benedikt Becker
Dr. med. Sophia Hook
Publikationsdatum
03.10.2022
Verlag
Springer Medizin
Erschienen in
Uro-News / Ausgabe 10/2022
Print ISSN: 1432-9026
Elektronische ISSN: 2196-5676
DOI
https://doi.org/10.1007/s00092-022-5508-7

Weitere Artikel der Ausgabe 10/2022

Uro-News 10/2022 Zur Ausgabe

Industrieforum

Industrieforum

Passend zum Thema

ANZEIGE
OnSite Advertorial Prostatitis
Phytotherapie bei CPPS

Pollstimol®: Leitliniengerechte Prostatitis-Therapie

In 90 % der Prostatitis-Fälle handelt es sich um eine chronische abakterielle Prostatitis (chronic pelvic pain syndrome, CPPS) mit anhaltender Entzündungsreaktion und Schwellung der Prostata. Als leitliniengerechte Behandlungsoption mit guter Evidenz hat sich das Phytotherapeutikum Pollstimol® etabliert.